Cognitive Trajectories Diverge by Genetic Risk in a Preclinical Longitudinal Cohort
Overview
Authors
Affiliations
Introduction: We sought to characterize the timing of changes in cognitive trajectories related to genetic risk using the apolipoprotein E (APOE) score, a continuous measure of Alzheimer's disease (AD) risk. We also aimed to determine whether that timing was different when genetic risk was measured using an AD polygenic risk score (PRS) that contains APOE.
Methods: We analyzed trajectories (N ≈1135) for four neuropsychological composite scores using mixed effects regression for longitudinal change across APOE scores and PRS of participants in the Wisconsin Registry for Alzheimer's Prevention, a longitudinal study of adults aged 40 to 70 at baseline, with a median participant follow-up time of 7.8 years.
Results: We found a significant non-linear age-by-APOE score interaction in predicting cognitive decline. Cognitive trajectories diverged by APOE score at approximately 65 years of age. A 0.5 standard deviation difference in cognition between extreme percentiles of the PRS was predicted to occur 1 to 2 years before that of the APOE score.
Discussion: Cognitive decline differs across time and APOE score. Estimates did not substantially shift with the AD PRS.
Highlights: The apolipoprotein E (APOE) score, a continuous measure, accounts for non-linear genetic risk of Alzheimer's disease. Non-linear age interacts with the APOE score to affect cognition. Cognitive decline starts to differ by APOE score levels at approximately age 65. Cognitive decline timing by polygenic risk (including APOE) is similar to APOE alone.
Rahman M, Harrison E, Biggs H, Seikus C, Elliott P, Breen G Nat Med. 2024; 30(6):1739-1748.
PMID: 38745010 PMC: 11186791. DOI: 10.1038/s41591-024-02960-5.
Pet Ownership, Living Alone, and Cognitive Decline Among Adults 50 Years and Older.
Li Y, Wang W, Zhu L, Yang L, Wu H, Zhang X JAMA Netw Open. 2023; 6(12):e2349241.
PMID: 38147332 PMC: 10751597. DOI: 10.1001/jamanetworkopen.2023.49241.
Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors.
Du L, Hermann B, Jonaitis E, Cody K, Rivera-Rivera L, Rowley H Brain Commun. 2023; 5(6):fcad333.
PMID: 38107504 PMC: 10724051. DOI: 10.1093/braincomms/fcad333.
Xu Y, Vasiljevic E, Deming Y, Jonaitis E, Koscik R, Van Hulle C J Alzheimers Dis. 2023; 94(4):1587-1605.
PMID: 37482996 PMC: 10468904. DOI: 10.3233/JAD-230097.